To The Moon

The Market Is Pricing Earnings. I Think Washington Is Pricing Permission.

For years, investing in UnitedHealth felt almost reassuringly straightforward. The company combined scale, disciplined execution and an unmatched healthcare ecosystem into a machine that compounded earnings with remarkable consistency. Investors debated medical cost trends, margins and valuation multiples, but rarely questioned whether the business model itself would remain politically acceptable.

That assumption deserves far more scrutiny today.

Healthcare still works. Permission is becoming the scarce asset

I think the real investment debate has quietly migrated from earnings power to something much harder to model: political licence. Investors continue to ask how quickly UnitedHealth can restore profitability after a bruising period, while I believe the more important question is whether policymakers are becoming increasingly uncomfortable with just how much of the healthcare journey one company controls.

That concern is no longer theoretical. The U.S. Department of Justice has challenged aspects of UnitedHealth's expansion strategy in recent years, while Congress has intensified scrutiny of pharmacy benefit managers—including Optum Rx—over drug pricing, rebates and market transparency. Several state attorneys general have also increased their examination of PBM practices. None of these actions alone determines the company's future, but together they suggest the regulatory mood has shifted.

That distinction matters because earnings disappointments usually recover with time. A shift in regulatory philosophy can alter an industry's economics for decades.

The Moat That Became the Spotlight

UnitedHealth's competitive advantage has never rested solely on selling insurance.

Its real strength is the integration of UnitedHealthcare, Optum Health, Optum Insight and Optum Rx into a single ecosystem. The company increasingly insures patients, manages their care, analyses their medical data and helps determine how medicines are purchased and reimbursed. Few competitors can replicate that breadth.

For years, investors celebrated this structure because it improved efficiency, generated valuable data and created significant economies of scale.

Ironically, that same architecture has become the centre of regulatory attention.

This is an unusual situation where the moat and the target are effectively the same asset.

The issue extends beyond simply owning multiple healthcare businesses. Increasingly, UnitedHealth's competitive advantage is built upon the enormous volume of clinical, claims and pharmacy data flowing through its integrated platform. Future rules governing data sharing, interoperability and transparency may ultimately prove just as significant as antitrust decisions. In a business where information increasingly functions as infrastructure, regulating data can become another way of regulating competitive advantage.

If regulators ultimately conclude that excessive vertical integration reduces competition or creates incentives that conflict with patient outcomes, the conversation may eventually move beyond financial penalties. Potential remedies could include stricter firewalls between UnitedHealthcare and parts of the Optum ecosystem, tighter operational separation between insurance and pharmacy benefit management, or, in a more extreme scenario, requiring divestitures of businesses such as Optum Rx. None of those outcomes appears imminent, but I think investors are too readily assuming that every legal challenge simply ends with another cheque being written.

Sometimes the expensive outcome is not the fine. It is losing strategic freedom.

The Financial Engine Still Looks Remarkably Healthy

That is precisely what makes $UnitedHealth(UNH)$ such a fascinating investment case.

Operationally, many parts of the business remain exceptionally strong.

Revenue kept climbing. The investment debate changed

Trailing twelve-month revenue has climbed to almost $450 billion, continuing a remarkable growth record that has seen revenue expand from around $288 billion in 2021. Even after a difficult period, the business continues to generate enormous cash flows from an exceptionally diversified customer base.

Management has also demonstrated that underlying demand for healthcare services remains robust. The company continues serving millions of Americans across employer-sponsored insurance, Medicare Advantage, Medicaid and commercial healthcare markets while Optum continues expanding its role throughout healthcare delivery.

Yet the income statement also reveals why investors became nervous.

Operating income has fallen sharply from more than $32 billion in both 2023 and 2024 to under $19 billion on a trailing twelve-month basis. Pretax income has experienced a similar decline as higher medical costs and operational pressures compressed profitability.

Revenue has remained resilient while margins have weakened, suggesting demand has not disappeared. Instead, the business is currently generating less profit from each additional dollar of revenue—a problem that is generally easier to repair than disappearing customers.

The Hidden Cost Investors Rarely Model

Here is the part I think receives surprisingly little attention.

Most valuation models assume regulatory investigations either conclude with fines or eventually disappear. Markets are generally comfortable discounting those possibilities because they can be estimated.

What proves much harder to quantify is the possibility that prolonged political uncertainty permanently increases a company's cost of capital.

If investors begin attaching a lasting regulatory discount to UnitedHealth, acquisitions become less attractive, strategic flexibility narrows and management becomes more conservative in allocating capital. Future investments that once appeared obvious suddenly require larger expected returns simply to compensate shareholders for elevated political risk.

That becomes less a dramatic collapse than a slow erosion. Investors often focus on earnings per share while quietly overlooking the valuation multiple they are willing to assign those earnings. Sometimes perception compounds just as powerfully as profit.

The Competitive Landscape Has Quietly Changed

UnitedHealth still enjoys advantages that competitors struggle to match.

Companies like $Elevance Health(ELV)$, $THE CIGNA GROUP(CI)$ and $CVS Health(CVS)$ have each built substantial healthcare platforms, but none combines insurance, physician networks, pharmacy benefit management and healthcare analytics at UnitedHealth's scale with quite the same operational integration.

Ordinarily, that would strengthen the investment case.

Today, however, I wonder whether being the industry's undisputed leader also means becoming the industry's preferred regulatory test case.

History suggests policymakers rarely begin reshaping industries by targeting smaller participants. They usually start with the largest.

Leadership can sometimes resemble wearing the tallest hat during a thunderstorm.

What Is the Market Already Pricing?

One obvious counterargument is that investors have already begun looking beyond the recent turbulence.

Confidence returned faster than regulatory uncertainty disappeared

After rebounding sharply from this year's lows, UnitedHealth now trades at around **22 times forward earnings**, reflecting a significant recovery in investor confidence alongside the share price. While that multiple remains broadly consistent with the company's long-term valuation range, it also suggests the market is becoming increasingly willing to treat recent operational and regulatory setbacks as temporary rather than structural.

That is precisely where I become more cautious.

If the current re-rating proves correct, today's valuation will eventually look entirely reasonable. But if Washington's scrutiny ultimately reshapes the economics of vertically integrated healthcare, investors may be assuming a faster return to business as usual than policymakers are prepared to allow.

The real question is no longer whether the shares look cheap. It is whether the market has already started removing a regulatory discount that may not have fully disappeared.

The next move may not belong to investors

Permission Granted?

I continue to believe $UnitedHealth(UNH)$ remains one of America's highest-quality healthcare franchises.

Its scale, diversified operations and extraordinary revenue-generating ability have not disappeared simply because recent headlines became uncomfortable. Indeed, many operational indicators suggest the underlying business retains significant resilience.

Nevertheless, I think investors risk framing the debate too narrowly around earnings recovery.

The more consequential issue is whether regulators are gradually redefining the acceptable boundaries of vertically integrated healthcare. If that philosophical shift gathers momentum, the long-term valuation framework investors have historically applied to UnitedHealth may require meaningful adjustment.

None of this means UnitedHealth is destined for structural change. It simply means investors should assign a higher probability to outcomes that were barely discussed only a few years ago.

That does not make the shares uninvestable.

It simply means I would be more cautious about assuming the recent recovery in investor confidence marks the end of the story. UnitedHealth remains a first-class business—but first-class businesses are not immune from first-class political risk.

After all, forecasting healthcare costs is difficult enough. Forecasting politicians may be the only activity capable of making actuaries feel fortunate.

@TigerStars @Daily_Discussion @Tiger_comments @Tiger_SG @Tiger_Earnings @TigerClub @TigerWire